Manufacturer
SANDOZ GMBH
Contents
Octreotide acetate
Indication
Acromegaly, Variceal haemorrhage in patients with cirrhosis, Prophylaxis of complications following pancreatic surgery, Secretory neoplasms, HIV-associated diarrhoea
Instruction
Administer via SC and IV Infusion
Drug interaction
Dosage adjustment of concurrent therapy may be necessary with calcium channel blockers, oral hypoglycaemics, β-blockers, diuretics. May increase concentration of bromocriptine.
Potentially Fatal: Requirements of insulin may be reduced requiring careful blood-glucose monitoring. Reduction in ciclosporin bioavailability and efficacy.
Malaysia
